MATERIALS AND METHODS

Case selection and TMA construction

Twenty cases (T1–T20) of invasive ductal carcinoma (IDC) were selected from the pathologic archives of Seoul National University Bundang Hospital after reviewing the Ki-67 immunostained slides upon diagnosis. All cases were surgically resected tissue specimens fixed in 10% formalin and paraffin-embedded in 2012. To analyze the effect of the presence of hot spots in Ki-67 measurement, we purposely chose 10 IDCs (T11–T20) which had localized high Ki-67 staining areas (Fig. 1). The remaining (T1–T10) showed a relatively even distribution of positive tumor cells. All twenty cases were arranged into a 2 mm, single-core TMA to set limits for the area of analysis, as opposed to whole section slides. TMA was constructed using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). Hot spot areas were selected to be incorporated into the TMA in 10 IDCs (T11–T20) while areas most representative of the tumor were selected for the remaining 10 cases (T1–T10) for TMA construction. This study was exempt from Institutional Review Board (IRB) deliberation (IRB No. X-1508/312-901).

Immunohistochemical staining and measurement of Ki-67

Immunohistochemical staining of Ki-67 was re-performed using MIB-1 clone (1:500; DAKO, Carpinteria, CA, USA) in whole sections and a TMA section. Four-micrometer-thick tissue sections were cut, dried, deparaffinized, and rehydrated following standard procedures. All sections were subjected to heat-induced antigen retrieval. Immunohistochemical staining was carried out in a BenchMark XT autostainer (Ventana Medical Systems, Tucson, AZ, USA) using an UltraView detection kit. All immunostained slides were scanned using ScanScope CS system (Aperio, Vista, CA, USA) and the files of such scanned slides were uploaded to an online system. Thirty different pathologists (O1–O30) from thirty different institutions (25 of which are academic teaching hospitals including all of the major hospitals in the country) participated in this study and examined the scanned slides using ImageScope viewing software with specific guidelines for Ki-67 measurement.

All observers measured Ki-67 index in two different ways for both whole section slides and a TMA slide. First, direct counting method consisted of counting at least 500 tumor cells in each of three representative areas in whole sections and counting of at least 500 tumor cells or all of the tumor cells (if the number of tumor cells were less than 500) in a TMA, either manually or digitally using an image analyzer, and the positive percentage was calculated; two out of 30 participants utilized DIA for direct counting. Second, rough estimation method consisted of visual estimation of Ki-67 index into five categories: 0 (<5%), 1 (5% to <10%), 2 (10% to <20%), 3 (20% to <50%), and 4 (≥50%). In tumors with hot spot areas (T11–T20), direct counting on whole section slides consisted of two different methods. The first was to count the number of positive tumor cells in one representative hot spot area which we designated as the “hot spot method.” The other method was counting in three representative areas including the hot spot and then calculating its average, which we named as the “average method.” For rough estimation, the observers made separate categorical estimations of Ki-67 from the hot spot and the entire field in whole section slides in tumors with hot spot areas (T11–T20). The schematic representation of study design and counting methods is provided in Fig. 2.

Statistical analyses

To assess interobserver variability in the 20 cases, we calculated intraclass correlation coefficient (ICC) with a 95% confidence interval (CI). Since there is no consensus on standard criteria for ICC, we used this value only for comparison of interobserver variabilities of different Ki-67 measurement methods. The ICC has a range of 0 to 1, with1 defining perfect agreement. To evaluate the distribution of Ki-67 proliferation indices measured by different observers for each case, we calculated the mean, median, standard error of mean, and standard deviation of each case, for every method. We drew a side by side box plot for Ki-67 indices. All data analyses were performed using IBM SPSS ver. 21.0.0 (IBM Co., Armonk, NY, USA).

RESULTS

Direct counting

The Ki-67 indices in each tumor calculated by direct counting in whole sections and a TMA are presented in Fig. 3. The mean and median values of Ki-67 indices were relatively lower in T1–T10 than in T11–T20 for both whole sections and TMA. To evaluate the effect of restricting area of measurement on Ki-67 counting, we compared the ICCs of Ki-67 indices in whole sections and TMA. The ICC of 20 cases among 30 observers was 0.802 (95% CI, 0.696 to 0.897) for whole sections by the average method. The ICC of Ki-67 indices measured in TMA was 0.895 (95% CI, 0.829 to 0.948). Because the TMA was constructed from the hot spot areas in T11–T20, we also compared the Ki-67 indices acquired by hot spot method in whole sections with those in TMA (Table 1). In T11–T20, the ICC of TMA was higher than that of whole sections using hot spot method (TMA: ICC, 0.895 [95% CI, 0.798 to 0.966]; whole section: ICC, 0.737 [95% CI, 0.561 to 0.905]).

To assess the effect of the presence of hot spots on direct counting, we compared the ICC of tumors without hot spots (T1–T10) with that of tumors with hot spots (T11–T20). Ki-67 indices using the average method were used for analysis in both T1–T10 and T11–T20. The ICC of T1–T10 was 0.874 with a 95% CI of 0.761–0.959, and the ICC of T11–T20 was 0.736 with a 95% CI of 0.559–0.904 in whole sections. The ICC of tumors with hot spots was significantly lower than that of tumors without hot spots using the same method of counting.

We also compared the ICC of two different counting methods applied in T11–T20: hot spot method versus average method (Table 1). In general, the mean Ki-67 indices resulting from the hot spot method was higher than those yielded using the average method. However, there was no difference between the ICC value of the former (ICC, 0.737 [95% CI, 0.561 to 0.905] and latter ICC, 0.736 [95% CI, 0.559 to 0.904]).

Categorical estimation

The Ki-67 indices in each tumor calculated by rough estimation for whole sections and TMAs are presented in Fig. 4. In whole sections, Ki-67 indices belonged to two categories in six cases, three categories in six cases, four categories in seven cases, and five categories in the remaining one case. In TMAs, they were assigned to one category in one case, two in six, three in eight, and four in the remaining five cases. Ki-67 for T15 in particular, showed a poor concordance between observers in the whole section. One observer assessed Ki-67 index as less than 5% while another assessed it as more than 50%. Rough estimation in TMA resulted in a narrower distribution of Ki-67 categories in six cases (T11 and T15 through 20) and a wider distribution of Ki-67 in three cases (T7, T10, and T14) compared with that in whole sections. Based on the distribution of Ki-67 indices, the rough estimation method was not better than the direct counting method.

Additionally, we compared the Ki-67 indices acquired by rough estimation in whole section using hot spot method with those in TMA for T11–T20 (Table 2). The distribution of Ki-67 categories was mainly restricted to two continuous categories in both platforms. In T11–T20, we also compared the Ki-67 indices acquired by categorical estimation in two different ways: hot spot method versus average method (Table 2). We observed that tumors tended to be categorized into higher categories and the range of distribution was decreased using the hot spot method compared with the average method.

DISCUSSION

Although Ki-67 index in breast cancer has predictive and prognostic values, it has not been accepted as a standard predictive or prognostic biomarker due to variability in its measurement. Thus, in this study, we performed a multicenter study to assess the degree of interobserver variability in Ki-67 index measurement and to find factors that contribute to its variability.

As there is no statistical criterion defining “high” concordance, one study assumed it to be having an ICC of approximately 0.9 [16]. The ICCs for various measurements taken in our study were in the range of 0.7–0.8. Thus, interobserver concordance in Ki-67 measurement was moderately good at best for all settings. We were, however, able to deduce some important conclusions from our study. With the participation of thirty different institutions, we evaluated interobserver variability in Ki-67 index measurement specifically depending on the area of selection, intratumoral heterogeneity, and counting method, which we held especially important among several factors that are known to influence Ki-67 measurement variability.

Previous studies evaluating interobserver variability of Ki-67 measurement have used either core biopsy samples or TMAs. However, this study is the first one, to our best knowledge, to have made direct comparisons between the whole section and TMA preparations from the same tumor sample. While restricting the area of counting increased concordance between the observers by a small amount (TMA: ICC, 0.895 [95% CI, 0.829 to 0.948]; whole section: ICC, 0.858 [95% CI, 0.774 to 0.929]), the difference was not significantly large. However, in tumors with hot spots (T11–T20), the ICC of TMA was much higher than that of whole sections using either average method or hot spot method (TMA: ICC, 0.895 [95% CI, 0.798 to 0.966]; whole section, average method: ICC, 0.736 [95% CI, 0.559 to 0.904]; whole section, hot spot method: ICC, 0.737 [95% CI, 0.561 to 0.905]). Similarly, in categorical estimation, the range of distribution in Ki-67 categories was decreased when counting in TMA in the cases with hot spots. Thus, restricting the area of counting seems to be a critical factor affecting concordance in Ki-67 measurement.

Because some breast cancers possess intratumoral heterogeneity in tumor cell proliferation, a manifestation of which is the presence of hot spots in Ki-67 expression, we attempted to analyze the degree of difference in Ki-67 measurement between observers in two ways. Dividing those cancers with and without hot spots and measuring ICCs of the two groups for the average counting method yielded an ICC of 0.874 for T1–T10 (95% CI, 0.761 to 0.959) and 0.736 (95% CI, 0.559 to 0.904) for T11–T20 in whole sections. Thus, the ICC of tumors with hot spots was much lower than that of tumors without hot spots; such finding that tumors with hot spots exhibit greater interobserver variability is not counterintuitive. A more interesting finding is that within this subset of tumors with hotspots, when we measured the degree of difference in Ki-67 measurement with regards to counting an average of the entire field or taking a single count from the hot spot only, there was no difference between the ICC value of the former (ICC, 0.736 [95% CI, 0.559 to 0.904]) and latter (ICC, 0.737 [95% CI, 0.561 to 0.905]). We expected that the ICC for whole section using hot spot method would be higher than that for whole section using average method. However, even within the hot spots, it was likely that observers chose different areas for counting, and the distribution of Ki-67–stained tumor nuclei was variable.

Interpretation of the weakly stained nuclei as either positive or negative staining may be an important factor contributing to variability in Ki-67 measurement. However, we did not investigate this interpretative issue in the current study. We used a mouse monoclonal antibody MIB-1 for Ki-67 immunostaining. It yielded similar yet less intense staining results compared with rabbit monoclonal antibody SP6 using the central laboratory equipment (data not shown). SP6 was employed in many previous pivotal studies [6,17-20] and showed increased sensitivity compared to mouse monoclonal antibodies [17,18,20]. However, the current recommendations from the International Ki-67 in Breast Cancer Working Group states only MIB-1 as the antibody endorsed in Ki-67 measurement [15,21]. Further comparative studies using different clones for Ki-67 and interpretation of weakly stained nuclei will be needed.

In order to assess interobserver variability depending on the counting method (in categories or direct numbers), each observer was instructed to take these two counting methods for each sample: for direct counting, more than five hundred cells were counted from at least three representative areas. For categorical counting, the observers made an estimate of the percentage of positive tumor cells into five categories (category 0, <5%; category 1, 5%–10%; category 2, 10%–20%; category 3, 20%–50%; and category 4, ≥50%). Although Ki-67 indices belonged to two categories in six cases on whole section and TMA (one case on TMA belonged to only one category), they had a wide distribution belonging to more than three categories in the remaining cases. Moreover, the cases with Ki-67 index within 10%–20%, which includes the cutoff value of 14% used for distinction of luminal A and luminal B subtypes in breast cancer, showed wide distribution in rough estimation from category 0 to 4. Therefore, rough estimation methods may be worse than direct counting method in terms of interobserver concordance.

A limitation of our study includes a small number of tumor samples. Although each tumor sample was presented in two platforms of whole section and TMA, and each observer made at least a few countings for each sample for various settings, the absolute sample number was only twenty, which is the major reason we restricted our statistical analysis to evaluating ICCs.

Finally, all of the observers were given the liberty of using either manual or digital counting, and two observers made direct counting via DIA. However, we were not able to make direct comparisons between the two methods due to the small sample size. DIA enables a much quicker measurement, and its clinical utility seems promising. One group has reported that automated Ki-67 measurement was almost as comparable as visual estimation in precision and prognostic ability [22], and Laurinavicius et al. [23] have suggested specific methodologies in using DIA for Ki-67 measurement. Standardization of DIA techniques may offer more consistent results between observers in the future, and its application using standard protocols should be studied in further studies.

In conclusion, our nationwide thirty-center study of Ki-67 interobserver variability showed that interobserver variability in measuring this critical biomarker is high. Although direct comparison between direct counting and rough estimation into categories was impossible due to statistical issues, direct counting seems to result in less interobserver variability. Thus, we recommend that Ki-67 measurement be performed by direct counting rather than by rough categorical estimation. Tumors with hot spots generally showed greater interobserver variability than those without hot spots. However, restricting the area of measurement to TMA platform resulted in decreased interobserver variability, even in tumors with hot spots. At this point, we cannot put down a specific number for the area of selection, and further studies are needed; however, we can propose that the area of selection should be confined to a specific area, such as the periphery of the tumor or hot spots (in cases with hot spots). Lastly, we urge future analyses comparing manual counting versus DIA in Ki-67 measurement since DIA seems to reduce not only intraobserver variability but also interobserver variability so that this critical biomarker can be used with a greater confidence in clinical practice.

Acknowledgments

Fig. 1.

A representative case with hot spots in Ki-67 immunohistochemistry. (A) Scan power view of Ki-67 immunostained slides with a hot spot in right lower corner. (B) High power view of the hot spot.

Fig. 2.

A schematic diagram of study design and counting methods. Twenty cases of invasive ductal carcinoma (IDC) were prepared in two platforms-whole sections and a tissue microarray (TMA), and then digitally scanned for analysis in online system. Each observer was instructed to measure Ki-67 index in two platforms in two different ways (direct counting or rough categorical estimation) employing the average method and hot spot method.

Fig. 3.

Side-by-side box plots of Ki-67 distribution using whole sections (A) and tissue microarray slides (B) in direct counting method. The box shows the first to third quartiles, the horizontal line inside the box represents the median, the whiskers extend to minimum and maximum values within 1.5 times the interquartile range (IQR) from the first and third quartiles. Outliers are represented by small circles and extreme values (more than 3 times IQR) by asterisks. The Ki-67 indices measured in whole section show wider distribution than those in tissue microarray.

Fig. 4.

Distribution of Ki-67 indices in whole sections (A) and tissue microarray slides (B) in categorical estimation. The Ki-67 indices measured by categorical estimation in whole sections and TMAs show a wide distribution in some cases.

REFERENCES

• 1. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-63. ArticlePubMedPMC
• 2. SØrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74. ArticlePubMedPMC
• 3. Perou CM, SØrlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52. ArticlePubMedPDF
• 4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74. ArticlePubMedPDF
• 5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. ArticlePubMed
• 6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50. ArticlePubMedPMC
• 7. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23. PubMedPMC
• 8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47. ArticlePubMedPMC
• 9. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 1992; 25: 31-40. ArticlePubMed
• 10. Luporsi E, André F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915. ArticlePubMedPMCPDF
• 11. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-83. ArticlePubMed
• 12. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in post-menopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-75. ArticlePubMedPMC
• 13. Penault-Llorca F, André F, Sagan C, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2809-15. ArticlePubMed
• 14. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-70. ArticlePubMed
• 15. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-64. PubMedPMC
• 16. Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-906. ArticlePubMedPMC
• 17. Wong SC, Chan JK, Lo ES, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med 2007; 131: 1047-55. ArticlePubMedPDF
• 18. Zabaglo L, Salter J, Anderson H, et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 2010; 63: 800-4. ArticlePubMed
• 19. Ekholm M, Beglerbegovic S, Grabau D, et al. Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility. Histopathology 2014; 65: 252-60. ArticlePubMed
• 20. Fasanella S, Leonardi E, Cantaloni C, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011; 6 Suppl 1: S7.ArticlePDF
• 21. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 1723-39. ArticlePubMed
• 22. Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106: 383-8. ArticlePubMedPMCPDF
• 23. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res 2014; 16: R35.ArticlePubMedPMCPDF

Figure & Data

References

Citations

Citations to this article as recorded by  

• Comparative analysis of Ki-67 labeling index morphometry using deep learning, conventional image analysis, and manual counting
  Mohammad Rizwan Alam, Kyung Jin Seo, Kwangil Yim, Phoebe Liang, Joe Yeh, Chifu Chang, Yosep Chong
  Translational Oncology.2025; 51: 102159.     CrossRef
• Machine Learning-Based Approaches for Breast Density Estimation from Mammograms: A Comprehensive Review
  Khaldoon Alhusari, Salam Dhou
  Journal of Imaging.2025; 11(2): 38.     CrossRef
• Letter re: A critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype
  M. Rizk, K. Mokbel
  ESMO Open.2025; 10(5): 105067.     CrossRef
• Ki-67 Testing in Breast Cancer: Assessing Variability With Scoring Methods and Specimen Types and the Potential Subsequent Impact on Therapy Eligibility
  Therese Bocklage, Virgilius Cornea, Caylin Hickey, Justin Miller, Jessica Moss, Mara Chambers, S. Emily Bachert
  Applied Immunohistochemistry & Molecular Morphology.2024; 32(3): 119.     CrossRef
• Interobserver agreement and diagnostic challenges of Congo red staining for amyloid detection on fat pad aspiration biopsies
  Levent Trabzonlu, T. Leif Helland, Melanie C. Kwan, Nathalie Kumiega, M. Lisa Zhang, Ivan Chebib, Vanda F. Torous
  Journal of the American Society of Cytopathology.2024; 13(5): 359.     CrossRef
• Assessment of the Predictive Role of Ki-67 in Breast Cancer Patients’ Responses to Neoadjuvant Chemotherapy
  Ghizlane Rais, Rania Mokfi, Farah Boutaggount, Meryem Maskrout, Soundouss Bennour, Chaymae Senoussi, Fadoua Rais
  European Journal of Breast Health.2024; : 199.     CrossRef
• Improving the accuracy of reporting Ki-67 IHC by using an AI tool
  Sahil Ajit Saraf, Aahan Singh, Wai Po Kevin Teng, Sencer Karakaya, M. Logaswari, Kaveh Taghipour, Rajasa Jialdasani, Li Yan Khor, Kiat Hon Lim, Sathiyamoorthy Selvarajan, Vani Ravikumar, Md Ali Osama, Priti Chatterjee, Santosh KV
  Heliyon.2024; 10(22): e40193.     CrossRef
• Predictive Value of Ki-67 Index in Evaluating Sporadic Vestibular Schwannoma Recurrence: Systematic Review and Meta-analysis
  Kunal Vakharia, Hirotaka Hasegawa, Christopher Graffeo, Mohammad H. A. Noureldine, Salomon Cohen-Cohen, Avital Perry, Matthew L. Carlson, Colin L. W. Driscoll, Maria Peris-Celda, Jamie J. Van Gompel, Michael J. Link
  Journal of Neurological Surgery Part B: Skull Base.2023; 84(02): 119.     CrossRef
• Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm
  Sho Kiritani, Junichi Arita, Yuichiro Mihara, Rihito Nagata, Akihiko Ichida, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
  Surgery.2023; 173(2): 365.     CrossRef
• Automated Molecular Subtyping of Breast Carcinoma Using Deep Learning Techniques
  S. Niyas, Ramya Bygari, Rachita Naik, Bhavishya Viswanath, Dhananjay Ugwekar, Tojo Mathew, J Kavya, Jyoti R Kini, Jeny Rajan
  IEEE Journal of Translational Engineering in Health and Medicine.2023; 11: 161.     CrossRef
• Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors
  Diana Grace Varghese, Jaydira Del Rivero, Emily Bergsland
  Cancers.2023; 15(14): 3712.     CrossRef
• Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues
  Laura Sophie Tribian, Maximilian Lennartz, Doris Höflmayer, Noémi de Wispelaere, Sebastian Dwertmann Rico, Clara von Bargen, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Veit Bertram, Christoph Fraune, Natalia Gorbokon, Sören Weidemann, C
  Diagnostics.2023; 13(20): 3242.     CrossRef
• AI-Powered Segmentation of Invasive Carcinoma Regions in Breast Cancer Immunohistochemical Whole-Slide Images
  Yiqing Liu, Tiantian Zhen, Yuqiu Fu, Yizhi Wang, Yonghong He, Anjia Han, Huijuan Shi
  Cancers.2023; 16(1): 167.     CrossRef
• Expression of estrogen and progesterone receptors, HER2 protein and Ki-67 proliferation index in breast carcinoma in both tumor tissue and tissue microarray
  UP Hacısalihoğlu, MA Dogan
  Biotechnic & Histochemistry.2022; 97(4): 298.     CrossRef
• Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of upper tract urothelial carcinoma: A retrospective cohort study from bench to bedside
  Che Hsueh Yang, Wei Chun Weng, Yen Chuan Ou, Yi Sheng Lin, Li Hua Huang, Chin Heng Lu, Tang Yi Tsao, Chao Yu Hsu, Min Che Tung
  Urologic Oncology: Seminars and Original Investigations.2022; 40(3): 109.e21.     CrossRef
• Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
  P. Tarantino, H.J. Burstein, N.U. Lin, I.E. Krop, E.P. Winer, S.J. Schnitt, E.P. Hamilton, S.A. Hurvitz, H.S. Rugo, G. Curigliano, S.M. Tolaney
  Annals of Oncology.2022; 33(3): 234.     CrossRef
• A novel deep classifier framework for automated molecular subtyping of breast carcinoma using immunohistochemistry image analysis
  Tojo Mathew, S. Niyas, C.I. Johnpaul, Jyoti R. Kini, Jeny Rajan
  Biomedical Signal Processing and Control.2022; 76: 103657.     CrossRef
• Deep learning for the standardized classification of Ki-67 in vulva carcinoma: A feasibility study
  Matthias Choschzick, Mariam Alyahiaoui, Alexander Ciritsis, Cristina Rossi, André Gut, Patryk Hejduk, Andreas Boss
  Heliyon.2021; 7(7): e07577.     CrossRef
• Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
  Fabio Marazzi, Roberto Barone, Valeria Masiello, Valentina Magri, Antonino Mulè, Angela Santoro, Federica Cacciatori, Luca Boldrini, Gianluca Franceschini, Francesca Moschella, Giuseppe Naso, Silverio Tomao, Maria Antonietta Gambacorta, Giovanna Mantini,
  Clinical Breast Cancer.2020; 20(5): e600.     CrossRef
• Study of Ki-67 index in the molecular subtypes of breast cancer: Inter-observer variability and automated scoring
  Divya Meermira, Meenakshi Swain, Swarnalata Gowrishankar
  Indian Journal of Cancer.2020; 57(3): 289.     CrossRef
• Improving the accuracy of gastrointestinal neuroendocrine tumor grading with deep learning
  Darshana Govind, Kuang-Yu Jen, Karen Matsukuma, Guofeng Gao, Kristin A. Olson, Dorina Gui, Gregory. E. Wilding, Samuel P. Border, Pinaki Sarder
  Scientific Reports.2020;[Epub]     CrossRef
• Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment
  Ah-Young Kwon, Ha Young Park, Jiyeon Hyeon, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong-Han Yu, Se Kyung Lee, Soo Youn Cho, Eun Yoon Cho, Irina V. Lebedeva
  PLOS ONE.2019; 14(2): e0212309.     CrossRef
• Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens
  Soomin Ahn, Junghye Lee, Min-Sun Cho, Sanghui Park, Sun Hee Sung
  Archives of Pathology & Laboratory Medicine.2018; 142(3): 364.     CrossRef
• Assessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes
  Sangjung Park, Sunyoung Park, Jungho Kim, Sungwoo Ahn, Kwang Hwa Park, Hyeyoung Lee
  Biomedical Science Letters.2018; 24(1): 9.     CrossRef
• Quantitative tumor heterogeneity assessment on a nuclear population basis
  Anne‐Sofie Wessel Lindberg, Knut Conradsen, Rasmus Larsen, Michael Friis Lippert, Rasmus Røge, Mogens Vyberg
  Cytometry Part A.2017; 91(6): 574.     CrossRef
• A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method
  Min Hye Jang, Hyun Jung Kim, Yul Ri Chung, Yangkyu Lee, So Yeon Park, William B. Coleman
  PLOS ONE.2017; 12(2): e0172031.     CrossRef
• A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
  Yi Zhang, Brock E. Schroeder, Piiha-Lotta Jerevall, Amy Ly, Hannah Nolan, Catherine A. Schnabel, Dennis C. Sgroi
  Clinical Cancer Research.2017; 23(23): 7217.     CrossRef